Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tirofiban.

P Théroux1

  • 1Department of Medicine, Montreal Heart Institute and University of Montreal, Québec, Canada.

Drugs of Today (Barcelona, Spain : 1998)
|September 16, 2003
PubMed
Summary
This summary is machine-generated.

Tirofiban effectively inhibits platelet aggregation by blocking the gpIIb/IIIa receptor. This review details its pharmacokinetics, pharmacodynamics, and clinical efficacy in cardiovascular conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel.

British journal of pharmacology·2011
Same author

Action of nifedipine in ischemic heart disease.

Canadian family physician Medecin de famille canadien·2011
Same author

Unstable angina and non-Q-wave myocardial infarction. Treatment beyond aspirin and heparin.

Cardiologia (Rome, Italy)·2002
Same author

Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy.

European heart journal·2002
Same author

An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.

European heart journal·2002
Same author

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.

Circulation·2001
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Platelet aggregation is crucial in thrombotic cardiovascular diseases.
  • The gpIIb/IIIa receptor plays a key role in platelet activation.

Purpose of the Study:

  • To review the pharmacokinetics and pharmacodynamics of tirofiban.
  • To summarize the efficacy and safety of tirofiban from phase III trials.
  • To discuss clinical applications of tirofiban.

Main Methods:

  • Review of pharmacokinetic and pharmacodynamic studies in healthy volunteers and patients.
  • Analysis of phase III clinical trial data for efficacy and safety.
  • Discussion of clinical use based on available evidence.

Main Results:

  • Tirofiban provides dose-related, reversible inhibition of platelet aggregation.

Related Experiment Videos

  • Efficacy demonstrated in unstable angina, myocardial infarction, and percutaneous coronary interventions.
  • Pharmacokinetics and pharmacodynamics evaluated in various patient populations, including those with renal or hepatic insufficiency.

    • Conclusions:

    • Tirofiban is a potent intravenous agent for inhibiting platelet aggregation.
    • The drug exhibits a favorable efficacy and safety profile in managing acute coronary syndromes and during PCI.
    • Understanding its pharmacokinetic and safety profile is essential for optimal clinical use.